Develops regenerative medicine treatments based on tissue engineering and cell therapy, centred on an autologous living bone implant for bone defect reconstruction and an allogeneic mesenchymal cell drug for inflammation and tissue damage. Intends to earn from product sales once clinical development is completed, marketing authorisations are obtained and production centres are established, supported by a commercialisation and distribution partner.
